TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$17.04M
MomentumView details →
1D Return
−1.90%
YTD Return
−64.45%
RSI (14)
46.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$17.04M
RSI (14)
46.7
MomentumView details →
1D Return
−1.90%
YTD Return
−64.45%
SummaryUpdated Jun 1, 2026
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage biotechnology company founded in 2011 and headquartered in South San Francisco, California. Originally established as a subsidiary of Inception Sciences, Inc., the company went public in November 2012. Tempest focuses on developing innovative small molecule therapeutics specifically designed to treat various forms of cancer, with a particular emphasis on targeting immune system pathways that can enhance the body's natural ability to fight tumors.
Similar companies
Latest newsMore news →
Justin Trojanowski resigned as Principal Financial Officer and Principal Accounting Officer of Tempest Therapeutics, Inc., effective September 1, 2026, and Nicholas Rossettos was appointed Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective the same date.12d agoNicholas Maestas resigned as Chief Financial Officer of Tempest Therapeutics, Inc., effective June 5, 2026, and Justin Trojanowski was appointed Vice President, Finance, Principal Financial Officer and Corporate Secretary, effective the same date.93d agoJohn David Yee was appointed as a Class II Director of Tempest Therapeutics, Inc., effective June 5, 2026.93d ago